155 related articles for article (PubMed ID: 19309394)
1. Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.
Faratian D; Graham A; Rae F; Thomas J
Histopathology; 2009 Mar; 54(4):428-32. PubMed ID: 19309394
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
3. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays?
Selvarajan S; Tan SY; Sii LH; Tan PH
Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720
[TBL] [Abstract][Full Text] [Related]
4. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
5. A testing algorithm for determination of HER2 status in patients with breast cancer.
Nichols DW; Wolff DJ; Self S; Metcalf JS; Jacobs D; Kneuper-Hall R; Cate JC
Ann Clin Lab Sci; 2002; 32(1):3-11. PubMed ID: 11848614
[TBL] [Abstract][Full Text] [Related]
6. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
Barberis M; Pellegrini C; Cannone M; Arizzi C; Coggi G; Bosari S
Am J Clin Pathol; 2008 Apr; 129(4):563-70. PubMed ID: 18343783
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray technology in the routine assessment of HER2 status in invasive breast cancer.
Cryan J; O'Grady A; Allen D; Kay E
Histopathology; 2009 Jun; 54(7):901. PubMed ID: 19635107
[No Abstract] [Full Text] [Related]
8. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
Bhargava R; Lal P; Chen B
Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
10. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
11. Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.
Franchet C; Filleron T; Cayre A; Mounié E; Penault-Llorca F; Jacquemier J; Macgrogan G; Arnould L; Lacroix-Triki M
Histopathology; 2014 Jan; 64(2):274-83. PubMed ID: 24117939
[TBL] [Abstract][Full Text] [Related]
12. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing.
Kay E; O'Grady A; Morgan JM; Wozniak S; Jasani B
J Clin Pathol; 2004 Nov; 57(11):1140-4. PubMed ID: 15509672
[TBL] [Abstract][Full Text] [Related]
13. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
Laakso M; Tanner M; Isola J
J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
[TBL] [Abstract][Full Text] [Related]
14. Tissue microarrays: construction and uses.
Fowler CB; Man YG; Zhang S; O'Leary TJ; Mason JT; Cunningham RE
Methods Mol Biol; 2011; 724():23-35. PubMed ID: 21370004
[TBL] [Abstract][Full Text] [Related]
15. HER-2 testing in breast cancer using parallel tissue-based methods.
Yaziji H; Goldstein LC; Barry TS; Werling R; Hwang H; Ellis GK; Gralow JR; Livingston RB; Gown AM
JAMA; 2004 Apr; 291(16):1972-7. PubMed ID: 15113815
[TBL] [Abstract][Full Text] [Related]
16. Miniature tissue microarrays for HercepTest standardisation and analysis.
Gulmann C; Loring P; O'Grady A; Kay E
J Clin Pathol; 2004 Nov; 57(11):1229-31. PubMed ID: 15509692
[TBL] [Abstract][Full Text] [Related]
17. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma.
Drev P; Grazio SF; Bracko M
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):179-84. PubMed ID: 18227723
[TBL] [Abstract][Full Text] [Related]
18. Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory.
Thomson TA; Zhou C; Chu C; Knight B
Am J Clin Pathol; 2009 Dec; 132(6):899-905. PubMed ID: 19926582
[TBL] [Abstract][Full Text] [Related]
19. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
Monego G; Arena V; Maggiano N; Costarelli L; Crescenzi A; Zelano G; Amini M; Capelli A; Carbone A
Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
[TBL] [Abstract][Full Text] [Related]
20. iCon-TMA for control and quantitation of immunohistochemistry and in situ molecular pathology analysis.
Petersen I; Blind C; Koepenik A; Dietel M; Krenn V
Pathol Res Pract; 2007; 203(8):629-31. PubMed ID: 17590280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
